Explainer | Are Asian countries choosing US or China for the Covid-19 vaccine?
- Indonesia, the Philippines have turned to Beijing; Singapore and Japan are partnering with US firms; while Thailand and India developing their own
- Experts say geopolitics factor into a particular nation’s choice, while pointing out the challenges inherent in wide-scale vaccinations
Ooi Eng Eong, deputy director of Duke-NUS’ emerging infectious diseases program, said the number of doses produced in the first batches would likely exceed the quantity required by Singapore and might be available for distribution to other countries.
Here is a look at the front-runners of the vaccine race, the ones Asian nations are eyeing, and the potential challenges of wide-scale vaccination.
06:17
‘Robust immune responses’ found in Covid-19 vaccine clinical trials point to 2021 release
WHO ARE THE KEY PLAYERS IN THE VACCINE RACE?
China, the initial epicentre of the Covid-19 outbreak, is among the countries at the forefront of the global vaccine race. In July, Chinese media reported that a vaccine developed by Tianjin-based CanSino Biologics and the country’s military research unit had shown some promise in early human testing.
Though it is set to launch a phase three trial, Beijing said the vaccine could already be used by the military. This makes CanSino the first company to have a coronavirus vaccine approved for limited use.
Other Chinese companies, including Beijing-based Sinovac and state-owned Sinopharm, have also launched their final phase three trials. The former will conduct trials in Brazil, while the latter is set to test its vaccines in the United Arab Emirates.
Duterte asks Filipinos to ‘endure’ coronavirus curbs until December, pins hopes on China vaccine
Switzerland is close to signing a deal to secure access for a coronavirus vaccine being developed by Moderna, according to a Swiss government official.
Russia is also hoping to bring two vaccines – one developed by Gamaleya Research Institute and the defence ministry, and the other by the Siberia-based Vector state research laboratory – to the market by the end of this year. Gamaleya has completed clinical trials for its vaccine, leading Russia’s health minister to prepare a mass vaccination campaign for October, according to local news agencies.
WHICH VACCINES ARE ASIAN NATIONS EYEING?
Falling in the first category is Indonesia, Southeast Asia’s largest economy. Its state-owned pharmaceutical company Bio Farma has been working with Sinovac to develop a coronavirus vaccine since April. It is set to launch phase three trials later this month, which if successful would herald production of up to 250 million doses a year.
The Philippines now has over 112,000 cases and is set to overtake Indonesia for the most cases in Southeast Asia.
Is India’s rush for a coronavirus vaccine being driven by national pride and China tensions?
When deciding on which vaccine to procure, Kavitha Hariharan, director of healthy societies at Marsh & McLennan Advantage, said safety and efficacy would be the top considerations but cost could not be discounted. This was especially the case for developing countries with large populations that had relatively lower health care spending per capita, she said.
Jeremy Lim, an associate professor at the National University of Singapore’s Saw Swee Hock School of Public Health, added that geopolitical reasons could also explain why some countries chose certain vaccines. He said that countries would “naturally align” to their broader national priorities beyond health.
Said Leong Hoe Nam, a Singapore-based infectious diseases expert: “If you look at the Philippines and Malaysia, there is also a strong Chinese overture to those countries, and we also saw China providing medical supplies to them so they are likely to get vaccine supplies from China easily.”
Leong added that the availability of a vaccine also played a part as demand would likely outpace supply.
01:57
Coronavirus: Inside a Chinese lab joining global race to find a vaccine
WHY IS THERE SCEPTICISM OVER VACCINES PRODUCED BY CHINA OR RUSSIA?
Last week, top US infectious diseases official Anthony Fauci said it was unlikely the US would use vaccines developed by either China or Russia, citing how their regulatory systems were far more opaque than in the West.
“I do hope that the Chinese and the Russians are actually testing the vaccine before they are administering the vaccine to anyone,” he told a US Congressional hearing on July 31. “Claims of having a vaccine ready to distribute before you do testing, I think, is problematic, at best.”
Leong said part of the reason for doubts over China-made vaccines could be due to “bad press” that Chinese companies have had in recent years, with “poor quality and ineffective” vaccines manufactured.
For example, in 2018, drug producer Changchun Changsheng violated standards in the making of some hundreds of thousands of vaccine doses for diphtheria, tetanus and whooping cough, administering 200,000 children with the defective product and causing paralysis in a few cases.
For Russia, Leong said the worry stemmed from the lack of medical publications on the vaccines. Other countries’ vaccine results were published, allowing scientists and researchers to scrutinise the findings and evaluate the data.
HOW DIFFICULT WILL IT BE TO ADMINISTER MASS VACCINATIONS?
Hariharan of Marsh & McLennan said one major challenge would be to convince enough people to get vaccinated, given how vaccines had been manufactured at unprecedented speeds and against the backdrop of rising vaccine hesitancy in many countries.
“Another challenge is affordability. Co-payments or out-of-pocket payments could discourage some people from getting vaccinated,” she said, also noting that there are initiatives, including Gavi, the vaccine alliance founded by the Bill & Melinda Gates Foundation.
Gavi had brought down prices for other vaccines by pooling demand from low-income countries, said Kavitha, who added that the alliance had also introduced Covax, a global financing scheme for Covid-19 vaccines.
Moderna coronavirus vaccine could be ready by end of year, US says
Leong, the infectious diseases physician, felt that while the government should foot most of the bill for the vaccine, he suggested that those from better-off backgrounds, such as “those of the middle class and above”, should pay a small portion of it. This, he said, would show that citizens were taking ownership of the vaccine.
Lim, the National University of Singapore professor, added that the administration of the vaccine would be a challenge for every country. While Singapore has rolled out mass vaccinations, such as for H1N1 influenza in 2009, most Southeast Asian countries do not have similar experience.
Lim said health care professionals, essential workers, and the most vulnerable segments of the population would likely be first in line for a vaccination.